Literature DB >> 19363261

Altered subcellular distribution of c-Abl in Alzheimer's disease.

Zheng Jing1, John Caltagarone, Robert Bowser.   

Abstract

c-Abl is a non-receptor tyrosine kinase that participates in multiple signaling pathways linking the cell surface, cytoskeleton, and the nucleus. Recent in vitro studies have also linked c-Abl to amyloid-beta-induced toxicity and tau phosphorylation. To further characterize a potential role of c-Abl in Alzheimer's disease (AD), we examined the expression and distribution of total and phosphorylated forms of c-Abl in the hippocampus of AD and control subjects. Laser scanning confocal microscopy was used to examine the colocalization of c-Abl with AD pathology. Our results demonstrate alterations in the presence and distribution of c-Abl and phosphorylated isoforms of c-Abl within the hippocampus during AD. Total unphosphorylated c-Abl was highest in non-demented control hippocampus. Activated isoforms of c-Abl were most abundant in AD hippocampus and co-localized with AD pathology, including granulovacuolar degeneration bodies, c-Abl interacts with phosphorylated tau in AD brain and may contribute to the formation of tau pathology. These studies demonstrate altered activation and distribution of c-Abl during AD, suggesting a role for c-Abl in Abeta signal transduction and generation of tau pathology in AD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19363261      PMCID: PMC2829466          DOI: 10.3233/JAD-2009-1062

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  38 in total

Review 1.  Abl: mechanisms of regulation and activation.

Authors:  Jodi M Smith; Bruce J Mayer
Journal:  Front Biosci       Date:  2002-01-01

Review 2.  c-Abl regulation: a tail of two lipids.

Authors:  Richard A Van Etten
Journal:  Curr Biol       Date:  2003-08-05       Impact factor: 10.834

3.  Activated c-Abl is degraded by the ubiquitin-dependent proteasome pathway.

Authors:  A Echarri; A M Pendergast
Journal:  Curr Biol       Date:  2001-11-13       Impact factor: 10.834

4.  Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease.

Authors:  X Zhu; A K Raina; C A Rottkamp; G Aliev; G Perry; H Boux; M A Smith
Journal:  J Neurochem       Date:  2001-01       Impact factor: 5.372

5.  Granulovacuolar degeneration of hippocampal pyramidal cells.

Authors:  B E Tomlinson; D Kitchener
Journal:  J Pathol       Date:  1972-03       Impact factor: 7.996

6.  Autoinhibition of c-Abl.

Authors:  Helma Pluk; Karel Dorey; Giulio Superti-Furga
Journal:  Cell       Date:  2002-01-25       Impact factor: 41.582

Review 7.  Regulation of F-actin-dependent processes by the Abl family of tyrosine kinases.

Authors:  Pamela J Woodring; Tony Hunter; Jean Y J Wang
Journal:  J Cell Sci       Date:  2003-07-01       Impact factor: 5.285

8.  Activation of the neuronal c-Abl tyrosine kinase by amyloid-beta-peptide and reactive oxygen species.

Authors:  Alejandra R Alvarez; Pablo C Sandoval; Nancy R Leal; Paula U Castro; Kenneth S Kosik
Journal:  Neurobiol Dis       Date:  2004-11       Impact factor: 5.996

Review 9.  The role of mitogen-activated protein kinase pathways in Alzheimer's disease.

Authors:  Xiongwei Zhu; Hyoung-gon Lee; Arun K Raina; George Perry; Mark A Smith
Journal:  Neurosignals       Date:  2002 Sep-Oct

Review 10.  Alzheimer's disease: beta-Amyloid protein and tau.

Authors:  Maho Morishima-Kawashima; Yasuo Ihara
Journal:  J Neurosci Res       Date:  2002-11-01       Impact factor: 4.164

View more
  28 in total

1.  Tau phosphorylated at tyrosine 394 is found in Alzheimer's disease tangles and can be a product of the Abl-related kinase, Arg.

Authors:  Matthew A Tremblay; Christopher M Acker; Peter Davies
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

2.  Neuronal c-Abl overexpression leads to neuronal loss and neuroinflammation in the mouse forebrain.

Authors:  Sarah D Schlatterer; Matthew A Tremblay; Christopher M Acker; Peter Davies
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 3.  c-Abl in neurodegenerative disease.

Authors:  Sarah D Schlatterer; Christopher M Acker; Peter Davies
Journal:  J Mol Neurosci       Date:  2011-07-05       Impact factor: 3.444

4.  Saitohin, which is nested within the tau gene, interacts with tau and Abl and its human-specific allele influences Abl phosphorylation.

Authors:  Yan Wang; Lei Gao; Christopher G Conrad; Athena Andreadis
Journal:  J Cell Biochem       Date:  2011-11       Impact factor: 4.429

Review 5.  Multifunctional Abl kinases in health and disease.

Authors:  Aaditya Khatri; Jun Wang; Ann Marie Pendergast
Journal:  J Cell Sci       Date:  2016-01-01       Impact factor: 5.285

6.  Involvement of c-Abl Kinase in Microglial Activation of NLRP3 Inflammasome and Impairment in Autolysosomal System.

Authors:  Vivek Lawana; Neeraj Singh; Souvarish Sarkar; Adhithiya Charli; Huajun Jin; Vellareddy Anantharam; Anumantha G Kanthasamy; Arthi Kanthasamy
Journal:  J Neuroimmune Pharmacol       Date:  2017-05-02       Impact factor: 4.147

7.  Role of zinc metallothionein-3 (ZnMt3) in epidermal growth factor (EGF)-induced c-Abl protein activation and actin polymerization in cultured astrocytes.

Authors:  Sook-Jeong Lee; Kyung-Sook Cho; Ha Na Kim; Hyun-Jae Kim; Jae-Young Koh
Journal:  J Biol Chem       Date:  2011-09-07       Impact factor: 5.157

8.  Abelson Kinases Mediate the Depression of Spontaneous Synaptic Activity Induced by Amyloid Beta 1-42 Peptides.

Authors:  M Reichenstein; N Borovok; A Sheinin; T Brider; I Michaelevski
Journal:  Cell Mol Neurobiol       Date:  2020-05-12       Impact factor: 5.046

9.  Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer's disease.

Authors:  Gunjan Dhawan; Colin K Combs
Journal:  J Neuroinflammation       Date:  2012-07-02       Impact factor: 8.322

10.  Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models.

Authors:  Michaeline L Hebron; Irina Lonskaya; Charbel E-H Moussa
Journal:  Hum Mol Genet       Date:  2013-05-10       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.